Molecular Partners

MOLN · Switzerland

Share price · MOLN

$2.67-1.63 (-37.88%) 3M

close as of 2026-11-18 · 24h delayed · vol 484 (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MOLN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-11.2%

    Nothing announced by MOLN that day or the session before.

  2. 28 Sep 2026-10.2%
  3. 18 Sep 2026+7.4%

    Nothing announced by MOLN that day or the session before.

  4. 12 Jun 2026+10.8%
  5. 22 May 2026+10.0%
  6. 30 Apr 2026-4.9%

    Nothing announced by MOLN that day or the session before.

  7. 8 Apr 2026+9.6%

    Nothing announced by MOLN that day or the session before.

  8. 18 Mar 2026+4.7%
  9. 13 Mar 2026-10.4%

Share of unusual movement by asset

For each asset, the share of MOLN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
MP0533
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—14%
Sessions with no dated event—84%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
MP0310No recent activity
Phase 1
FAP x 4-1BB (CD137)Protein / enzyme therapeutic
Solid Tumors
Advanced Solid Tumors
Phase 1
CD33;CD123;CD70 x CD3Multispecific antibody
Acute Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$0$13M$103M+ $41M short-term inv.$25Mreport ↗

Molecular Partners reported revenue of $0M, down 100.0% YoY, R&D spend of $12.98M, down 10.3% YoY, cash and equivalents of $103.39M, and a net loss of $24.72M for Q2 2025.

Figures only: this period's report disclosed no narrative text

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2$1.7M$14M$73M+ $104M short-term inv.$17Mreport ↗
2023-Q2$0.5M$13M$71M+ $173M short-term inv.$18Mreport ↗
2022-Q2$12M$13M$120M+ $178M short-term inv.$4.7Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$48M$104M+ $13M short-term inv.$19M-$62M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$5.6M$55M$71M+ $95M short-term inv.$15M-$67M operating cash flowreport ↗
2023-FY$7.8M$54M$80M+ $142M short-term inv.$17M-$66M operating cash flowreport ↗
2022-FY$199M$53M$95M+ $174M short-term inv.—$124M operating cash flowreport ↗
2021-FY$10M$61M$79M+ $67M short-term inv.$17M-$99M operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 4 reporting institutions held 3.6M shares ($14.2M).

#InstitutionSharesValue
1SUVRETTA CAPITAL MANAGEMENT, LLC2,221,494$8.8M
2BVF INC/IL1,353,968$5.4M
3SmartHarvest Portfolios, LLC15,543$62K
4MORGAN STANLEY367$1K